Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring
Antineoplastic Agents
/ administration & dosage
Bile Duct Neoplasms
/ drug therapy
Cholangiocarcinoma
/ drug therapy
Disease-Free Survival
Female
Humans
Male
Maximum Tolerated Dose
Middle Aged
Pyrazoles
/ administration & dosage
Pyrimidines
/ administration & dosage
Pyrroles
/ administration & dosage
Receptor, Fibroblast Growth Factor, Type 1
/ antagonists & inhibitors
Journal
Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
02
06
2021
revised:
16
08
2021
accepted:
20
09
2021
pubmed:
24
9
2021
medline:
15
3
2022
entrez:
23
9
2021
Statut:
ppublish
Résumé
Futibatinib, a highly selective, irreversible FGFR1-4 inhibitor, was evaluated in a large multihistology phase I dose-expansion trial that enrolled 197 patients with advanced solid tumors. Futibatinib demonstrated an objective response rate (ORR) of 13.7%, with responses in a broad spectrum of tumors (cholangiocarcinoma and gastric, urothelial, central nervous system, head and neck, and breast cancer) bearing both known and previously uncharacterized
Identifiants
pubmed: 34551969
pii: 2159-8290.CD-21-0697
doi: 10.1158/2159-8290.CD-21-0697
pmc: PMC9762334
doi:
Substances chimiques
Antineoplastic Agents
0
Pyrazoles
0
Pyrimidines
0
Pyrroles
0
futibatinib
4B93MGE4AL
FGFR1 protein, human
EC 2.7.10.1
Receptor, Fibroblast Growth Factor, Type 1
EC 2.7.10.1
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
402-415Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Informations de copyright
©2021 The Authors; Published by the American Association for Cancer Research.
Références
J Clin Oncol. 2017 Jan 10;35(2):157-165
pubmed: 27870574
Cancers (Basel). 2020 Sep 11;12(9):
pubmed: 32932925
Clin Cancer Res. 2017 Sep 15;23(18):5366-5373
pubmed: 28615371
N Engl J Med. 2019 Jul 25;381(4):338-348
pubmed: 31340094
Cancer Discov. 2013 Sep;3(9):1058-71
pubmed: 23744832
J Clin Oncol. 2018 Feb 20;36(6):536-542
pubmed: 29320312
Oncogene. 1997 Mar 27;14(12):1397-406
pubmed: 9136983
Nat Rev Cancer. 2010 Feb;10(2):116-29
pubmed: 20094046
Cancer Res. 2013 Aug 15;73(16):5195-205
pubmed: 23786770
J Bone Miner Res. 2011 Oct;26(10):2486-97
pubmed: 21812026
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
Mol Cancer Ther. 2020 Mar;19(3):847-857
pubmed: 31911531
J Clin Oncol. 2018 Jan 20;36(3):276-282
pubmed: 29182496
Ann Oncol. 2017 Jun 01;28(6):1316-1324
pubmed: 29177434
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
N Engl J Med. 2020 Sep 24;383(13):1207-1217
pubmed: 32955176
Clin Cancer Res. 2019 Aug 15;25(16):4888-4897
pubmed: 31088831
Eur Urol. 2017 Jun;71(6):858-862
pubmed: 28108151
Neuro Oncol. 2017 Apr 1;19(4):475-483
pubmed: 27852792
Ann Oncol. 2020 Oct;31(10):1405-1412
pubmed: 32622884
Lancet Oncol. 2020 May;21(5):671-684
pubmed: 32203698
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
Ann Oncol. 2017 Jun 1;28(6):1207-1216
pubmed: 28327938
Cancer Discov. 2021 Feb;11(2):326-339
pubmed: 33218975
Cancer Discov. 2020 May;10(5):657-663
pubmed: 32029534
Br J Cancer. 2017 Nov 21;117(11):1592-1599
pubmed: 28972963
Cancer Discov. 2013 Jun;3(6):636-47
pubmed: 23558953
Cancer Res. 2018 Oct 1;78(19):5668-5679
pubmed: 30115694
Cancer Discov. 2016 Aug;6(8):838-851
pubmed: 27179038
Clin Cancer Res. 2016 Aug 1;22(15):3884-93
pubmed: 26936917
J Clin Oncol. 2020 Jul 20;38(21):2407-2417
pubmed: 32463741
Lancet Oncol. 2019 Oct;20(10):1454-1466
pubmed: 31405822
Cancer Discov. 2017 Mar;7(3):252-263
pubmed: 28034880
Br J Cancer. 2019 Jan;120(2):165-171
pubmed: 30420614
Neoplasia. 2013 Aug;15(8):975-88
pubmed: 23908597
Nature. 2018 Feb 8;554(7691):189-194
pubmed: 29420467
Eur J Cancer. 2018 Mar;91:47-55
pubmed: 29331751
Cancer Discov. 2019 Aug;9(8):1064-1079
pubmed: 31109923
Nat Rev Clin Oncol. 2019 Feb;16(2):105-122
pubmed: 30367139
Oncogene. 2015 Apr 23;34(17):2167-77
pubmed: 24909170
Clin Cancer Res. 2016 Jan 1;22(1):259-67
pubmed: 26373574
ChemMedChem. 2019 Feb 19;14(4):494-500
pubmed: 30600916
Lancet Gastroenterol Hepatol. 2021 Oct;6(10):803-815
pubmed: 34358484
ACS Chem Biol. 2015 May 15;10(5):1319-29
pubmed: 25686244
Oncotarget. 2017 Feb 28;8(9):16052-16074
pubmed: 28030802
Mol Oncol. 2019 Apr;13(4):738-756
pubmed: 30537101
Cancer Res. 2020 Nov 15;80(22):4986-4997
pubmed: 32973082